Ian Neeland, MD, of University Hospitals Harrington Heart & Vascular Institute, talks about the uptick in patients at his practice seeking semaglutide for weight loss.
The increased demand for semaglutide to treat obesity has lead to more referrals for weight loss management, but challenges arise in conversations with patients due to insurance coverage limitations, with some patients unable to afford the medication despite its effectiveness. According to Ian Neeland, MD, these conversations prompt comprehensive evaluations, counseling on potential side effects, and a pharmacist-led dose escalation protocol to facilitate the transition for those who can access it.
Neeland serves as director of cardiovascular prevention and codirector of the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease at the University Hospitals Harrington Heart & Vascular Institute, as well as associate professor of medicine at Case Western Reserve University School of Medicine.
Transcript
Have you observed an increase in the demand for semaglutide as a treatment for obesity, and how has this affected your practice and the conversations you have with patients?
So the answer is, have I seen an uptick in interest in weight loss with semaglutide? For sure. A lot of people have been referred to me and our program for weight loss specifically. It's definitely an appropriate referral to have that conversation and to medically assess one's status with regard to risk factors in the setting of living with obesity or overweight, and also what options there might be. As a cardiologist, I don't specifically do chronic weight management with these patients, although I definitely get plenty of referrals for that reason, and what I'll usually offer is a referral to one of our chronic weight management programs that we have in our institution. But I many times will start a GLP-1 [glucagon-like peptide 1] receptor agonist for the patient, if it's for the obesity indication.
It's a difficult conversation sometimes to have, because often insurance does not cover chronic weight management for these medications, and so the patient would have to pay out of pocket. Some of my patients are well-to-do and can afford that cost, [but] many others cannot. It's unfortunate because we have something to offer individuals, but many times they can't get it, and not because of the shortage, per se, just because of the cost of the medication. And certainly over time with more options in the market, those costs will likely come down as things go generic. But for the meantime, it can be a difficult conversation to have with patients that we have effective medications but I'm not sure you can utilize it because you can't necessarily afford it and insurance won't cover it.
But when a patient comes looking for Wegovy for weight loss, obviously you want to do a comprehensive evaluation of their medical history [and] what potential indications or contraindications may there be to GLP-1s and for weight loss. Obviously, counseling and education about potential side effects and ways to mitigate those effects is very important, and also a plan going forward. What we utilize here is a pharmacist-led dose escalation protocol where the pharmacist will assess side effects [and] assess how the patient's [responding to] the medication before going to the next level. So that eases that transition and facilitates it for patients so they can get to the maximum tolerated dose and most effective dose that works for them, so that's how we kind of handle that situation.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Review: One-Shot Etranacogene Dezaparvovec Represents Game-Changing Gene Therapy for Hemophilia B
May 3rd 2024More than 20 years of gene therapy clinical research have led to etranacogene dezaparvovec’s use in hemophilia B, according to authors of a recent review—and it takes its place in a line of current and potentially many future genomic medicines for a range of diseases.
Read More